Skip to main content
Premium Trial:

Request an Annual Quote

OvaGene Opens Clinical, Research Lab

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OvaGene Oncology today announced the opening of its new clinical and research laboratory in Irvine, Calif., where the company is headquartered.

The facility will serve as the central headquarter for operations, research, and molecular clinical lab testing, OvaGene said in a statement. Technologies used for genomic testing on cancer cells at the facility include qPCR, comparative genomic hybridization, and gene expression arrays.

OvaGene is in the process of pursuing clinical laboratory licensure and accreditation. If it is successful, the company will offer molecular diagnostics to the gynecological community, it said. In addition, the company will develop diagnostics based on in-licensed technologies and internal research. The research will include collaborations with pharma firms in the oncology space in order to develop companion diagnostics.

OvaGene develops and commercializes personalized DNA-based diagnostics for gynecologic cancer.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.